Merck up after FDA approves combination treatment for muscle invasive bladder cancer

Shares of drugmaker Merck MRK.N up 5.4% at $100.1

U.S. FDA says it has approved Merck's combination therapy to treat muscle invasive bladder cancer

Merck's Keytruda in combination with enfortumab vedotin-ejfv, developed by Astellas Pharma 4503.T and Seagen, now acquired by Pfizer PFE.N, is approved as a immunotherapy to reduce tumor size, kill cancer cells, and improve surgical outcomes

Muscle-invasive bladder cancer is a more aggressive cancer that has grown into the muscle layer of the bladder wall that has high risk of spreading to other parts of the body and requires aggressive treatment

Including session's move, stock up 0.25% YTD